Cantitate/Preț
Produs

Prescription Drug Pricing

Editat de Jonathan R. Dickson, Amy M. Woebler
en Limba Engleză Hardback – 20 feb 2012
The growing cost of brand-name prescription drugs can be a burden on patients, payers and providers of health care, particularly when price increases are large and occur suddenly. Controlling rising prescription drug prices helps to ensure that patients can afford medically necessary and sometimes life-saving medication, and to moderate costs for hospitals and third-party payers such as insurance plans and state and federal governments. This book examines prescription drug pricing costs and control concerns with a focus on extraordinary price increases for brand-name prescription drugs, as well as the characteristics and factors that contributed to this price increase.
Citește tot Restrânge

Preț: 75000 lei

Preț vechi: 102711 lei
-27% Nou

Puncte Express: 1125

Preț estimativ în valută:
14353 14894$ 11997£

Carte disponibilă

Livrare economică 22 februarie-08 martie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781613246399
ISBN-10: 1613246390
Pagini: 147
Ilustrații: illustrations
Dimensiuni: 157 x 232 x 14 mm
Greutate: 0.38 kg
Editura: Nova Science Publishers Inc

Cuprins

Preface; Prescription Drugs: Trends in Usual & Customary Prices for Commonly Used Drugs; Lack of Therapeutically Equivalent Drugs & Limited Competition May Contribute to Extraordinary Price Increases; Overview of Approaches to Control Prescription Drug Spending in Federal Programs; Opening Statement of U.S. Senator Amy Klobuchar, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry"; Statement of Senator Charles E Schumer, Chairman, Joint Economic Committee, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry"; Statement of Madeline M Carpinelli, Stephen W Schondelmeyer, PRIME Institute, College of Pharmacy, University of Minnesota, Before the Joint Economic Committee, Hearing on "Extraordinary Price Increases in the Pharmaceutical Market"; Testimony of Alan L Goldbloom, MD, President & CEO, Children's Hospitals & Clinics of Minnesota, before the Joint Economic Committee, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry"; Testimony of Danielle Foltz, before the Joint Economic Committee, Hearing on "At What Cost? Egregious Price Increases in the Pharmaceutical Drug Industry"; Entry Threats & Pricing in the Generic Drug Industry; Index.